Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749468 | 1.00 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL1719719 | 1.00 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL7920805 | 0.94 | PPARG (0.55) | PPARGPPARA | |
| SCHEMBL1719565 | 0.92 | PPARG (0.53) | PPARGPPARA | |
| SCHEMBL1720449 | 0.92 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL7921154 | 0.91 | PPARG (0.62) | PPARGPPARA | |
| SCHEMBL4159916 | 0.91 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL1720475 | 0.89 | PPARG (0.50) | PPARG | |
| SCHEMBL1720416 | 0.88 | PPARG (0.53) | PPARG | |
| SCHEMBL2217249 | 0.88 | PPARG (0.76) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7423172-B2 | Tyrosine derivatives as PPAR-γ-modulators | LABORATORIOS SALVAT, S.A. (ES) | 2008-09-09 | — | — | US | disclosed |
| EP-1778624-B1 | TYROSINE DERIVATIVES AS PPAR-GAMMA-MODULATORS | SALVAT LAB SA (ES) | 2008-08-20 | — | — | EP | disclosed |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | LABORATORIES SALVAT, S.A. (ES) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | PPARG 1/4885PPARA 4/4885 |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.